TY - JOUR
T1 - The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions
AU - Great Global Res Acute Conditions
AU - Motiejunaite, Justina
AU - Akiyama, Eiichi
AU - Cohen-Solal, Alain
AU - Maggioni, Aldo Pietro
AU - Mueller, Christian
AU - Choi, Dong-Ju
AU - Kavoliuniene, Ausra
AU - Celutkiene, Jelena
AU - Parenica, Jiri
AU - Lassus, Johan
AU - Kajimoto, Katsuya
AU - Sato, Naoki
AU - Miro, Oscar
AU - Peacock, W. Frank
AU - Matsue, Yuya
AU - Voors, Adriaan A.
AU - Lam, Carolyn S. P.
AU - Ezekowitz, Justin A.
AU - Ahmed, Ali
AU - Fonarow, Gregg C.
AU - Gayat, Etienne
AU - Regitz-Zagrosek, Vera
AU - Mebazaa, Alexandre
N1 - Funding Information:
The work of J.M., J.C., and A.K. was supported by the Research Council of Lithuania (MIP-049/2015). Y.M. is supported by the JSPS (Japan Society for the Promotion of Science) Postdoctoral Fellowships for Research Abroad. The Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) study is supported by grants from National Medical Research Council of Singapore; Agency for Science, Technology, and Research Biomedical Research Council; Asian Network for Translational Research and Cardiovascular Trials Program; Boston Scientific Investigator Sponsored Research Program; and Bayer.
Funding Information:
Conflict of interest: A.C.-S. has received grants or honoraria from Novartis, Servier, Daiichi Sankyo, Vifor, Menarini, and Cardiorentis. A.K. has received research grants from Research Council of Lithuania; investigator fees from AstraZeneca, Novartis, Pfizer, Bayer; consulting fees from Servier and Pfizer; speaker honoraria from Berlin-Chemie Menarini, Bayer, Sevier, Novartis, and Pfizer. A.M. reports personal fees from Novartis, Orion, Roche, Servier, Sanofi, Otsuka, Philips; grants and personal fees from Adrenomed and Abbott; grants from 4TEEN4, outside the submitted work. A.P.M. reports personal fees from Bayer and Novartis, outside the submitted work. C.M. has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the Stiftung für kardiovaskuläre Forschung Basel; Abbott, Alere, AstraZeneca, Beckman Coulter, Biomerieux, Brahms, Roche, Siemens, Singulex, Sphingotec, and the Department of Internal Medicine, University Hospital Basel, as well as speaker honoraria/consulting honoraria from Abbott, Alere, AstraZeneca, Biomerieux, Boehringer Ingelheim, BMS, Brahms, Cardiorentis, Novartis, Roche, Siemens, and Singulex. C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Roche Diagnostics, Medtronic, and Vifor Pharma; and has consulted for AstraZeneca, Bayer, Novartis, Amgen, Merck, Janssen Research and Development LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, and Takeda. E.G. reports personal fees from Roche Diagnostics, Magnisense, and Edwards Lifescience; grants from Retia Medical and Deltex Medical; grants from Sphingotec, outside the submitted work. W.F.P. reports research grants from Abbott, Braincheck, Immunarray, Janssen, Ortho Clinical Diagnostics, Relypsa, Roche. Consultant: Abbott, AstraZeneca, Bayer, Beckman, Boehrhinger-Ingelheim, Ischemia Care, Dx, Immunarray, Instrument Labs, Janssen, Nabriva, Ortho Clinical Diagnostics, Relypsa, Roche, Quidel, Siemens. Expert Testimony: Johnson and Johnson. Stock/Ownership Interests: AseptiScope Inc., Brainbox Inc., Comprehensive Research Associates LLC, Emergencies in Medicine LLC, Ischemia DX LLC. G.C.F. received consulting fees for Abbott, Amgen, Bayer, Janssen, Novartis, and Medtronic and served as principal investigator for OPTIMIZE-HF which was funded by GlaxoSmithKline. J.A.E. reports research grants or
Funding Information:
consulting fees from Sanofi, Bristol-Myers Squibb, Bayer, Merck, Trevena, Novartis, and Amgen. J.C≤. has received speaker and investigator fees from Servier, Novartis, Grindex, Berlin-Chemie Menarini, and Roche Diagnostics. K.K. has received research grants from AstraZeneca, Ono Pharmaceutical, Tsumura, Daiichi Sankyo, Novartis, Astellas Pharma, MSD, Pfizer Japan, Research Institute for Production Development, Takeda Pharmaceutical, Kyowa Hakko Kirin, Chugai Pharmaceutical, Mochida Pharmaceutical, and Mitsubishi Tanabe Pharma, and honoraria from Mochida Pharmaceutical, Pfizer Japan, Research Institute for Production Development, Sumitomo Dainippon Pharma and Kyowa Hakko Kirin. N.S. has received honoraria from Otsuka, Takeda, Ono, Boehringer Ingelheim, and Daiichi Sankyo; has received research support from Roche Diagnostics Japan; and has served as consultant for Terumo, Otsuka, and Bristol-Myers Squibb. O.M. reports honoraria for consultory from Novartis and The Pharmaceutical Company. V.R.-Z. reports speaker fees from Pfizer and Bristol-Myers Squibb. Y.M. is affiliated with a department endowed by Philips Respironics, ResMed, Teijin Home Healthcare, and Fukuda Denshi, and received an honorarium from Otsuka Pharmaceutical Co. All other authors declared no conflict of interest.
Publisher Copyright:
© 2020 The Authors. Published on behalf of the European Society of Cardiology. All rights reserved.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Aims: Recent data from national registries suggest that acute heart failure (AHF) outcomes might vary in men and women, however, it is not known whether this observation is universal. The aim of this study was to evaluate the association of biological sex and 1-year all-cause mortality in patients with AHF in various regions of the world. Methods and results: We analysed several AHF cohorts including GREAT registry (22 523 patients, mostly from Europe and Asia) and OPTIMIZE-HF (26 376 patients from the USA). Clinical characteristics and medication use at discharge were collected. Hazard ratios (HRs) for 1-year mortality according to biological sex were calculated using a Cox proportional hazards regression model with adjustment for baseline characteristics (e.g. age, comorbidities, clinical and laboratory parameters at admission, left ventricular ejection fraction). In the GREAT registry, women had a lower risk of death in the year following AHF [HR 0.86 (0.79-0.94), P < 0.001 after adjustment]. This was mostly driven by northeast Asia [n = 9135, HR 0.76 (0.67-0.87), P < 0.001], while no significant differences were seen in other countries. In the OPTIMIZE-HF registry, women also had a lower risk of 1-year death [HR 0.93 (0.89-0.97), P < 0.001]. In the GREAT registry, women were less often prescribed with a combination of angiotensin-converting enzyme inhibitors and beta-blockers at discharge (50% vs. 57%, P = 0.001). Conclusion: Globally women with AHF have a lower 1-year mortality and less evidenced-based treatment than men. Differences among countries need further investigation. Our findings merit consideration when designing future global clinical trials in AHF.
AB - Aims: Recent data from national registries suggest that acute heart failure (AHF) outcomes might vary in men and women, however, it is not known whether this observation is universal. The aim of this study was to evaluate the association of biological sex and 1-year all-cause mortality in patients with AHF in various regions of the world. Methods and results: We analysed several AHF cohorts including GREAT registry (22 523 patients, mostly from Europe and Asia) and OPTIMIZE-HF (26 376 patients from the USA). Clinical characteristics and medication use at discharge were collected. Hazard ratios (HRs) for 1-year mortality according to biological sex were calculated using a Cox proportional hazards regression model with adjustment for baseline characteristics (e.g. age, comorbidities, clinical and laboratory parameters at admission, left ventricular ejection fraction). In the GREAT registry, women had a lower risk of death in the year following AHF [HR 0.86 (0.79-0.94), P < 0.001 after adjustment]. This was mostly driven by northeast Asia [n = 9135, HR 0.76 (0.67-0.87), P < 0.001], while no significant differences were seen in other countries. In the OPTIMIZE-HF registry, women also had a lower risk of 1-year death [HR 0.93 (0.89-0.97), P < 0.001]. In the GREAT registry, women were less often prescribed with a combination of angiotensin-converting enzyme inhibitors and beta-blockers at discharge (50% vs. 57%, P = 0.001). Conclusion: Globally women with AHF have a lower 1-year mortality and less evidenced-based treatment than men. Differences among countries need further investigation. Our findings merit consideration when designing future global clinical trials in AHF.
KW - Acute heart failure
KW - Gender
KW - Biological sex
KW - Mortality
KW - Prognosis
KW - GENDER-RELATED DIFFERENCES
KW - CONTEMPORARY MANAGEMENT
KW - EJECTION FRACTION
KW - MORTALITY
KW - PREDICTORS
KW - AGE
U2 - 10.1093/eurheartj/ehaa071
DO - 10.1093/eurheartj/ehaa071
M3 - Article
SN - 0195-668X
VL - 41
SP - 1357
EP - 1364
JO - European Heart Journal
JF - European Heart Journal
IS - 13
ER -